Business
Radiopharm Theranostics tanks on ASX debut – The Australian Financial Review
The paper value of chairman Paul Hopper’s 35.5 per cent stake fell from $54 million to $36 million in just a few hours.
The early stage company does not have revenue from licence arrangements or product sales. It is developing a platform of radiopharmaceutical products for diagnostic and therapeutic cancer treatment.
Shanghai-based NanoMab Technologies is the second-largest…
Continue Reading
-
Noosa News16 hours agoAustralia Zoo reunites with the Ukrainian community
-
Noosa News16 hours ago“Hidden gem”: last chance for renovated bayside homes below $1m
-
General24 hours agoChina was the big disruptor in our region. Now the US is determined to take that title
-
General24 hours agoSpaceX to invest $3 billion in Musk’s xAI startup